Wuhan vaccine factory restarted

Testing confirms manufacturing of new doses being done properly

Vaccines produced by one of the drug companies embroiled in the recent vaccine scandal might be available as a supplement for children who had previously taken substandard doses, since production has resumed, authorities said.

The Wuhan Institute of Biological Products, which was reported to have produced a batch of 400,520 doses of substandard diphtheria, tetanus and whooping cough vaccines (DTaP) for infants, has passed an inspection and resumed production, according to the State Drug Administration.